Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E66.12 EPS (ttm)2.50 Insider Own0.20% Shs Outstand255.15M Perf Week-8.55%
Market Cap42.13B Forward P/E38.71 EPS next Y4.27 Insider Trans-40.57% Shs Float254.41M Perf Month-7.71%
Income646.80M PEG1.16 EPS next Q1.06 Inst Own97.68% Short Float1.51% Perf Quarter-6.03%
Sales2.83B P/S14.89 EPS this Y327.00% Inst Trans1.26% Short Ratio2.97 Perf Half Y5.69%
Book/sh11.40 P/B14.48 EPS next Y11.71% ROA18.40% Target Price196.32 Perf Year11.61%
Cash/sh11.98 P/C13.79 EPS next 5Y56.86% ROE30.20% 52W Range136.50 - 194.92 Perf YTD10.18%
Dividend- P/FCF38.32 EPS past 5Y47.60% ROI8.80% 52W High-15.29% Beta1.65
Dividend %- Quick Ratio3.60 Sales past 5Y10.30% Gross Margin86.90% 52W Low20.96% ATR6.75
Employees2300 Current Ratio3.70 Sales Q/Q35.70% Oper. Margin22.50% RSI (14)39.78 Volatility4.08% 4.14%
OptionableYes Debt/Eq0.20 EPS Q/Q220.50% Profit Margin26.70% Rel Volume1.44 Prev Close166.67
ShortableYes LT Debt/Eq0.20 EarningsOct 24 AMC Payout0.00% Avg Volume1.29M Price165.11
Recom1.80 SMA20-4.40% SMA50-7.63% SMA200-1.74% Volume1,854,824 Change-0.94%
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Nov-16-18 07:57AM  Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
Nov-14-18 07:25AM  Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-18 08:12AM  Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss Zacks
Nov-08-18 10:27AM  Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down Zacks
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks
09:15AM  Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down Zacks
08:00AM  9 Blue Chip Giants That Will Crush the S&P 500 Investopedia
Nov-01-18 07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
04:00AM  Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene Business Wire
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 09:48AM  Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
Oct-29-18 09:12AM  Vertex Pharmaceuticals Waits to Hit the Triple Motley Fool
Oct-28-18 09:33AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation Motley Fool
Oct-27-18 08:31AM  AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated Motley Fool
Oct-26-18 08:15AM  Edited Transcript of VRTX earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-18 12:31PM  Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates Zacks
08:00AM  Today's Research Reports on Trending Tickers: Vertex Pharmaceuticals and Celgene ACCESSWIRE
Oct-24-18 08:23PM  Vertex Pharmaceuticals Inc (VRTX) Q3 2018 Earnings Conference Call Transcript Motley Fool -6.36%
05:15PM  Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates Zacks
04:10PM  Vertex: 3Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Third-Quarter 2018 Financial Results Business Wire
08:22AM  Vertex Pharmaceuticals Q3 Earnings Outlook Benzinga
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
12:08PM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
11:22AM  What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings? Zacks
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
06:33AM  Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc. Motley Fool
Oct-19-18 05:41PM  Why Proteostasis Therapeutics Tumbled 23.2% on Friday Motley Fool
01:02PM  UAB researchers leading way on drug regimen battling cystic fibrosis American City Business Journals
10:27AM  Why Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is A Financially Healthy Company Simply Wall St.
07:54AM  Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene Business Wire
Oct-18-18 01:34PM  Growth Stocks Smacked Again As Market Correction Intensifies Investor's Business Daily
11:45AM  Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis Business Wire
Oct-17-18 10:31AM  Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up? Zacks
09:30AM  CELG vs. VRTX: Which Stock Should Value Investors Buy Now? Zacks
Oct-16-18 04:01PM  Vertex to Announce Third Quarter 2018 Financial Results on October 24 Business Wire
Oct-12-18 02:23PM  3 High-Reward Stocks From 3 Emerging Trends InvestorPlace
12:48PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
Oct-11-18 08:49AM  Why CRISPR Therapeutics Stock Is Heading Higher Today Motley Fool
06:25AM  CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial Investopedia
Oct-10-18 05:11PM  After-hours buzz: SQ, FLR & more CNBC
05:03PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
04:12PM  Crispr stock up 8% as company says FDA accepted new-drug application MarketWatch
04:01PM  CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
10:10AM  Why the Earnings Surprise Streak Could Continue for Vertex (VRTX) Zacks
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-05-18 02:53PM  7 Fast-Growing Stocks to Buy Today InvestorPlace
Oct-01-18 08:02AM  Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines Business Wire
Sep-28-18 08:16AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV Motley Fool
Sep-26-18 04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
Sep-16-18 08:31AM  Is CRISPR Therapeutics AG a Buy? Motley Fool
Sep-12-18 06:01AM  3 Top Healthcare Stocks to Buy in September Motley Fool
Sep-11-18 04:01PM  Vertex to Present at the Morgan Stanley Healthcare Conference on September 14 Business Wire
Sep-10-18 09:11AM  Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility Business Wire
Sep-07-18 10:45AM  Vertex Completes Enrollment in Triple Combination Studies Zacks
08:58AM  Lilly, Teva, Pfizer & Others Await FDA Decisions in September Zacks
Sep-06-18 08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
08:00AM  Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis Business Wire
Sep-05-18 09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
09:16AM  Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock Motley Fool
Sep-04-18 09:45AM  An Apple A Day Can't Keep Strong Gains Away From These 5 Hot Medical Stocks Investor's Business Daily
09:40AM  Vertex Inks Reimbursement Agreement for Orkambi in Australia Zacks
Sep-03-18 03:00AM  Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation Business Wire
Sep-02-18 09:10AM  3 Biotech Stocks That Could Soar Next Week Motley Fool
01:00AM  Vertex's Cystic Fibrosis Medicine to Be Subsidized in Australia Bloomberg
Sep-01-18 12:00PM  3 Stocks That Could Put Netflix's Returns to Shame Motley Fool
Aug-31-18 11:34AM  Vertex Inks Deal With Genomics to Make Serious Disease Drugs Zacks
Aug-30-18 09:39AM  Vertex (VRTX) Hits Fresh High: Is There Still Room to Run? Zacks
08:02AM  The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration Benzinga
02:00AM  Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines Business Wire
Aug-24-18 11:46AM  Why Is Vertex (VRTX) Up 0.1% Since Last Earnings Report? Zacks
08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-23-18 09:18AM  4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings Zacks
09:10AM  Mallinckrodt's Stannsoporfin Gets Complete Response Letter Zacks
03:00AM  Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations Business Wire
Aug-22-18 11:43AM  Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco Zacks
10:15AM  Stocks Lower Amid Trump Troubles; This Top Retail Stock Breaks Out Investor's Business Daily
Aug-21-18 04:01PM  IBD Stock Of The Day: Vertex Pharma Nears Third Breakout Of 2018 Investor's Business Daily
08:32AM  Looking for a Growth Stock? Why It is Time to Focus on Vertex Pharmaceuticals (VRTX) Zacks
Aug-20-18 04:47PM  Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin Zacks
08:45AM  Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International Zacks
Aug-17-18 09:44AM  4 Winning Stocks With Solid Efficiency Level Zacks
08:53AM  Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now? Zacks
Aug-16-18 10:04AM  Vertex Awards Two College Students Full Scholarships to the University of Massachusetts Business Wire
09:07AM  Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children Zacks
Aug-15-18 04:39PM  Vertex cystic fibrosis drug gets expanded approval for use in infants Reuters
03:29PM  FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene Business Wire
08:48AM  The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue Benzinga
Aug-14-18 10:55AM  Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit Zacks
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga
Aug-10-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
10:00AM  Is Crispr Therapeutics Stock Grossly Overvalued? Motley Fool
09:27AM  Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2 Zacks
09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 04:18PM  3 Top Biotech Stocks to Buy in August Motley Fool
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Silva Paul MSVP & Corp ControllerJul 12Option Exercise90.2986077,64916,947Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86641,734Jul 16 04:37 PM
Silva Paul MSVP & Corp ControllerJul 12Sale175.02860150,51716,087Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Sale175.022,125371,91839,609Jul 16 04:37 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41343,859Jul 09 06:14 PM
Parini MichaelEVP, CL&AOJul 05Sale168.384,250715,61539,609Jul 09 06:14 PM
Sachdev AmitEVP, CROJun 29Option Exercise88.904,096364,14850,758Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Option Exercise91.502,957270,56917,376Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Option Exercise89.153,708330,57850,460Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Option Exercise131.8923,3753,082,92970,074Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Option Exercise87.1313,4451,171,39783,444Jul 03 04:29 PM
Sachdev AmitEVP, CROJun 29Sale167.634,096686,61546,662Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Sale166.522,957492,38516,087Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Sale169.003,708626,65246,752Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Sale166.3023,3753,887,17346,699Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Sale164.9844,3317,313,59639,113Jul 03 04:29 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Option Exercise83.36106,5008,877,840297,260Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Option Exercise109.144,250463,84550,949Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Option Exercise109.144,250463,84551,002Jun 26 05:20 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Sale160.00140,21122,433,760157,049Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Sale160.004,250680,00046,699Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Sale159.004,250675,75046,752Jun 26 05:20 PM
Bhatia Sangeeta N.DirectorJun 04Sale152.05875133,0444,879Jun 05 05:39 PM
Silva Paul MSVP & Corp ControllerMay 15Sale155.7820131,31216,087May 16 05:27 PM
Parini MichaelEVP, CL&AOMay 15Sale155.788513,24139,609May 16 05:24 PM
SMITH IAN FEVP, COOMay 15Sale155.7821733,80446,699May 16 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale155.7813821,49846,752May 16 05:11 PM
Sachdev AmitEVP, CROMay 15Sale155.788312,93046,662May 16 05:06 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale155.789815,26669,999May 16 04:48 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,330201,59241,939May 04 04:23 PM
Parini MichaelEVP, CL&AOMay 03Sale149.502,330348,33539,609May 04 04:23 PM
SMITH IAN FEVP, COOApr 26Option Exercise108.6553,1255,771,98999,824Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Option Exercise122.4538,2504,683,71377,859Apr 27 04:38 PM
Parini MichaelEVP, CL&AOApr 26Sale159.5638,2506,103,17039,609Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 26Sale160.1253,1258,506,37546,699Apr 27 04:37 PM
SMITH IAN FEVP, COOApr 25Option Exercise84.4514,1721,196,78678,667Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Option Exercise90.292,125191,86642,123Apr 27 04:38 PM
Parini MichaelEVP, CL&AOApr 25Sale155.222,514390,23339,609Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Sale155.3331,9684,965,52646,699Apr 27 04:37 PM
Silva Paul MSVP & Corp ControllerApr 18Option Exercise90.2985977,55916,946Apr 19 05:37 PM